Forte Biosciences, Inc. (FBRX): Price and Financial Metrics
GET POWR RATINGS... FREE!
FBRX Stock Price Chart Interactive Chart >
FBRX Price/Volume Stats
| Current price | $1.01 | 52-week high | $1.78 |
| Prev. close | $1.01 | 52-week low | $0.90 |
| Day low | $0.98 | Volume | 47,600 |
| Day high | $1.02 | Avg. volume | 40,678 |
| 50-day MA | $1.00 | Dividend yield | N/A |
| 200-day MA | $1.16 | Market Cap | 20.54M |
Forte Biosciences, Inc. (FBRX) Company Bio
Forte Biosciences Inc. operates as a clinical-stage dermatology company in the United States. It is developing a live biotherapeutic FB-401 that has completed Phase 1/2a clinical trial to treat inflammatory skin diseases for pediatric atopic dermatitis patients. The company is based in Torrance, California.
Latest FBRX News From Around the Web
Below are the latest news stories about FORTE BIOSCIENCES INC that investors may wish to consider to help them evaluate FBRX as an investment opportunity.
Forte Biosciences GAAP EPS of -$0.18 misses by $0.03Forte Biosciences press release (FBRX): Q3 GAAP EPS of -$0.18 misses by $0.03.“Forte is making excellent progress with its lead program FB-102, which is a direct result of the… |
Dr. Scott Brun, M.D. Appointed to Forte Biosciences Board of DirectorsForte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), announced today that Dr. Scott Brun, M.D. has been appointed to the Forte Biosciences Board of Directors. Dr. Brun is currently a Venture Partner at Abingworth and in addition to his consulting practice, he is also a Senior Advisor for Horizon Therapeutics, and a Senior Medical Advisor at Launch Therapeutics. Dr. Brun previously served |
Forte Biosciences, Inc. Announces Third Quarter 2022 Results and Provides Business UpdateForte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced third quarter 2022 results and provided a business update. “Forte is making excellent progress with its lead program FB-102, which is a direct result of the team’s hard work and diligent efforts. FB-102 holds significant potential in a variety of indications |
Large Forte Biosciences shareholder scolds company board of directorsFunicular Funds, which owns 8% of the outstanding shares of Forte Biosciences (FBRX), excoriated the company board of directors in a letter over a recent capital raise. |
Camac Partners Condemns Forte Biosciences’ Seemingly Defensive and Unjustifiable Capital RaiseNEW YORK, August 17, 2022--Camac Partners, LLC (together with its affiliates, "Camac" or "we"), which is one of the largest shareholders of Forte Biosciences, Inc. (Nasdaq: FBRX) ("Forte" or the "Company"), today expressed concerns regarding the Company’s sizable trading price discount relative to its cash on hand and the Board of Directors’ (the "Board") decision to conduct a highly dilutive equity capital raise following the emergence of four separate Schedule 13D filers. |
FBRX Price Returns
| 1-mo | -1.94% |
| 3-mo | -7.76% |
| 6-mo | -12.17% |
| 1-year | -34.42% |
| 3-year | -22.39% |
| 5-year | -96.99% |
| YTD | 1.00% |
| 2022 | -53.27% |
| 2021 | -64.73% |
| 2020 | 355.24% |
| 2019 | -93.51% |
| 2018 | -19.90% |
Loading social stream, please wait...